Please assess the completion status of the following clinical trial:

Trial Title: Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients with age of 18-80 years;~2. Presentation with silent ischemia, stable angina, or non-ST-segment elevation acute coronary syndrome with GRACE score \<140 on admission;~3. PCI only with implantation of current generation drug-eluting stent(s) for coronary artery disease during the present admission \[current generation DES refers to DES with thin cobalt-chromium or platinum-chromium struts, with a durable or biodegradable polymer eluting a rapamycin-analogue antiproliferative agent. The current major DES available in China market include: EXCEL and EXCEL 2 (JW Medical System, Weihai, China), Tivoli（Essen Technology, Beijing, China), Endeavor Resolute (Medtronic Inc., Minnesota, USA), FireHawk (MicroPort Medical (Group) Co., Ltd, Shanghai, China), BuMA (SinoMedical,China),Xience V (Abbott Laboratories, Abbott Park, Illinois, USA), Xience Prime (Abbott Laboratories, Abbott Park, Illinois, USA), Promus Element and Synergy (BostonTechnologies, Massachusetts, USA)\].~4. PCI resulted in complete revascularization (successful PCI treatment of all epicardial coronary lesions with diameter stenosis \>70% or intermediate lesions with FFR ≤0.80);~5. Intended treatment with dual antiplatelet therapy (aspirin + clopidogrel) after the DES procedure for at least 6 months;~6. Agreement to comply with all study procedures.~7. Written informed consent provided.~Exclusion Criteria:~1. Presentation with STEMI;~2. Left main disease (diameter stenosis \>30% );~3. Any prior coronary stent implantation during the last year prior to the index procedure;~4. Implantation of of first-generation drug-eluting stents or bioabsorbable scaffolds during the index procedure;~5. Implantation of \>4 stents during the index procedure;~6. Any prior stent thrombosis;~7. Any active gastrointestinal bleeding or ulcers, or prior gastrointestinal bleeding or ulcers within the last 24 months;~8. Prior gastrointestinal tract or abdominal surgery other than simple procedures which would not change the gastrointestinal tract anatomy, such as polyp removal, cholecystectomy or appendectomy;~9. Contraindications to the AMCE test, including suspected or known gastrointestinal obstruction, stenosis, fistula, diverticula, etc.; presence of gastrointestinal obstruction symptoms such as pain or dysphagia; inoperative conditions or refusal to undergo abdominal surgery if required (i.e, if the capsule will not pass and cannot be removed by endoscopy)~10. Severe hemorrhoids (phase 3-4 according to guidelines of American Society of Colon and Rectal Surgery);~11. LVEF \<0.40 on admission according to cardiac ultrasound;~12. Renal dysfunction (eGFR \<30ml/min/1.73m2);~13. Active hepatitis or ALT \>3 times upper limits of normal on admission;~14. Uncontrolled severe hypertension (\>180/110mmHg);~15. Hemoglobin \<100 g/L;~16. Platelet count \<100×109/L;~17. Planned use of a proton pump inhibitor, gastric mucosa protectant or any other antacid agent after study enrollment；~18. Required use of oral anticoagulation (warfarin or other factor II or factor X inhibitors);~19. Inability to take 12-month DAPT for any reason;~20. Mandatory use of \>6 month DAPT (i.e. contraindication to aspirin or clopidogrel monotherapy after 6 months);~21. Any comorbidity with estimated survival time \<12 months (e.g. progressive cancer, chronic obstructive lung disease, etc.);~22. Any contraindication to MRI examination, including implantation of an MRI-incompatible pacemaker, defibrillator, or other ferromagnetic material; etc.~23. Pregnant or plan to be pregnant within 1 year;~24. Any condition that may interfere with any study procedures, such as dementia, immobility, alcohol use, etc.;~25. Planned surgery within 1 year;~26. Taking iron supplement;~27. Participating in any other clinical trial of an investigational drug or device that has not met its primary endpoint.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin+clopidogrel (Type: ACTIVE_COMPARATOR): Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks).
- Aspirin (Type: EXPERIMENTAL): Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks).
- Clopidogrel (Type: EXPERIMENTAL): Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).